FDA Ends Emergency Use for Three Old COVID Tests
Published Date: 6/26/2026
Notice
Summary
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
BD Veritor EUA Revoked Feb 24, 2026
FDA revoked the Emergency Use Authorization (EUA) for the BD Veritor System for Rapid Detection of SARS-CoV-2 effective February 24, 2026. BD requested the revocation, told FDA there are no viable BD Veritor reagents remaining in U.S. distribution, and has transitioned to a cleared BD Veritor product under K243872; the revoked EUA device is no longer authorized for emergency COVID-19 detection or diagnosis.
InBios SCoV-2 Detect EUA Revoked Feb 24, 2026
FDA revoked the Emergency Use Authorization (EUA) for InBios International, Inc.'s SCoV-2 Detect Neutralizing Ab ELISA effective February 24, 2026. InBios requested the revocation and stated there are no viable SCoV-2 Detect Neutralizing Ab ELISA reagents remaining in U.S. distribution; the revoked EUA device is no longer authorized for emergency COVID-19 detection or diagnosis.
Roche Elecsys EUA Revoked March 2, 2026
FDA revoked the Emergency Use Authorization (EUA) for Roche Diagnostics' Elecsys Anti-SARS-CoV-2 effective March 2, 2026. Roche requested the revocation, indicated there are no viable Elecsys reagents remaining in U.S. distribution, and has transitioned to a cleared Elecsys product under K250768; the revoked EUA device is no longer authorized for emergency COVID-19 detection or diagnosis.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19921, Determination That SULFADIAZINE (Sulfadiazine) Tablet, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 500 mg sulfadiazine tablet wasn’t taken off the market because it was unsafe or didn’t work. This means generic drug makers can now apply to sell their versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.
2026-19850, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503
The FDA is asking for public feedback on how it collects info about food and color additives, including their labels and safety petitions. This affects companies that want to add or change ingredients in food and how they submit their paperwork electronically. Comments are due by October 29, 2026, and the process helps keep food safe without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-12893, Combined Notice of Filings #1
Big energy players like Southwestern Electric Power and Appalachian Power are making moves to take over wind energy projects, which could shake up how electricity is generated and managed. The Federal Energy Regulatory Commission is reviewing these changes and some rate updates that might affect costs starting June 1, 2026. If you want to weigh in, comments are due by July 13, 2026, so don’t miss your chance!
Next: 2026-12907, Evaluation of the California Coastal Management Program; Notice of Public Meetings; Request for Comments
NOAA is checking in on California’s Coastal Management Program and wants your thoughts! They’re hosting one in-person meeting and two online meetings in August 2026 to hear from folks about spaceports, oil, pipelines, desalination, and undersea cables. If you care about California’s coast, now’s the time to speak up before the August 22 deadline—no money changes yet, just your chance to shape the future!